欧盟再增购1亿剂辉瑞疫苗 南韩洽购Moderna约4,000万剂疫苗
欧盟委员会主席冯德莱恩表示,欧盟将再购买1亿剂辉瑞(PFE.US)与BioNTech(BNTX.US)的疫苗,令总购买量增至3亿剂。
BioNTech行政总裁Ugur Sahin表示,额外的1亿剂疫苗将在明年交付。欧盟亦有望在明年1月批准紧急使用美国药厂Moderna(MRNA.US)的疫苗,欧盟已预订8,000万剂,之後可再购买8,000万剂。
另外,Moderna表示,正在与南韩政府讨论供应4,000万或更多剂量的疫苗,预计将在明年第二季开始分销往当地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.